Dr. Reddy's Laboratories Ltd.

Industry

  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
  • Digital Health
    • Disease Management

Other Names/Subsidiaries

  • American Remedies and Development B.V.
  • Aurigene
  • Aurigene Discovery Technologies
  • Aurigene Oncology
  • Dr. Reddy’s Research
  • Dr. Reddy's Research and Development B.V.
  • Imperial Credit
  • Litaphar Laboratorios
  • OctoPlus N.V.
  • Promius Pharma
  • Wockhardt
See more in Biomedtracker

Latest on Dr. Reddy's Laboratories Ltd.

Scrip

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s

Scrip

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 
• By Anju Ghangurde

Big Pharma’s global capability centers (GCCs) in India are evolving well beyond being just “cost efficiency outposts” and transitioning, in some cases, to emerge as centers of excellence (CoEs) unlock

Scrip

Asia Deal Watch: Dr. Reddy’s Gets Regional Rights To Pair Of Bio-Thera Biosimilars

 
• By Joseph Haas, Jung Won Shin, and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Dr. Reddy’s Acquires Rights From

Generics Bulletin

Dr Reddy’s Bags Rights To Two More Biosimilars In Deal With Bio-Thera

 
• By Dave Wallace

Dr Reddy’s has gained rights to a pair of proposed Stelara (ustekinumab) and Simponi (golimumab) biosimilars in multiple markets in south-east Asia, after striking an exclusive commercialization agree